Fusion startups face divide over early public market entry

At The Economist’s Fusion Fest in London last week, the mood was buoyed by fusion startups raising $1.6 billion in the last 12 months. However, a deep divide is emerging over when these capital-intensive companies should go public. In the last four months, TAE Technologies and General Fusion have announced plans to merge with publicly traded companies to secure capital. These moves have sparked intense debate over whether it is too early for fusion companies to enter public markets before achieving key technical milestones.

The financial details of these planned transactions highlight the immense capital requirements of the sector:

• TAE Technologies: The company announced its merger with Trump Media & Technology Group in December. TAE has received $200 million of a potential $300 million in cash from the deal. The remainder will reportedly land once the company files its S-4 form—a registration statement—with the U.S. Securities and Exchange Commission. Prior to the merger, TAE raised nearly $2 billion, matching its pre-merger valuation of $2 billion.
• General Fusion: The company announced in January that it plans to go public via a reverse merger—a process where a private company lists publicly by merging with an existing public entity. The deal could net the company $335 million and value the combined entity at $1 billion. Last year, General Fusion laid off 25% of its staff, and though it received a $22 million investment lifeline in August, it required more capital.

Some observers worry that these companies are going public too early. Neither TAE nor General Fusion has achieved scientific breakeven—the milestone where a fusion reaction generates more energy than it needs to ignite. One executive noted that “if they were in those shoes, they’re not sure how they would fill time on quarterly earnings calls if the companies didn’t hit scientific breakeven soon.” If these companies fail to deliver, there is concern that public markets could sour on the entire fusion sector.

The sector remains split on whether to pursue near-term revenue through side businesses or wait for a working power plant. Some companies are embracing revenue now: Commonwealth Fusion Systems and Tokamak Energy plan to sell magnets, while TAE and Shine Technologies operate in nuclear medicine. Others, like Inertia Enterprises, remain laser-focused on power plants. The industry is watching which milestone will trigger future listings: scientific breakeven, facility breakeven (when a reactor makes more energy than the site needs to operate), or commercial viability (when a reactor makes enough electricity to sell to the grid). Commonwealth Fusion Systems expects to hit scientific breakeven next year, which could trigger a public listing.

Why it matters

Fusion startups are facing a critical divide on whether to pursue public market listings before achieving key scientific milestones like ‘scientific breakeven.’ This tension is exacerbated by the need for capital to sustain long-term R&D versus the pressure to demonstrate commercial viability to shareholders.